BR9408025A - Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases - Google Patents

Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases

Info

Publication number
BR9408025A
BR9408025A BR9408025A BR9408025A BR9408025A BR 9408025 A BR9408025 A BR 9408025A BR 9408025 A BR9408025 A BR 9408025A BR 9408025 A BR9408025 A BR 9408025A BR 9408025 A BR9408025 A BR 9408025A
Authority
BR
Brazil
Prior art keywords
therapeutic use
metalloproteinase inhibitors
peptidyl compounds
matrix metalloproteinase
diseases
Prior art date
Application number
BR9408025A
Other languages
English (en)
Inventor
John Montana
Jonathon Dickens
David Alan Owen
Andrew Douglas Baxter
Original Assignee
Chiroscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiroscience Ltd filed Critical Chiroscience Ltd
Publication of BR9408025A publication Critical patent/BR9408025A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
BR9408025A 1993-11-10 1994-11-10 Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases BR9408025A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (1)

Publication Number Publication Date
BR9408025A true BR9408025A (pt) 1996-12-17

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9408025A BR9408025A (pt) 1993-11-10 1994-11-10 Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases

Country Status (22)

Country Link
US (1) US5853623A (pt)
EP (1) EP0728144B1 (pt)
JP (1) JPH09505041A (pt)
KR (1) KR960705843A (pt)
CN (1) CN1134705A (pt)
AT (1) ATE188969T1 (pt)
AU (1) AU679286B2 (pt)
BR (1) BR9408025A (pt)
CA (1) CA2173470A1 (pt)
CZ (1) CZ287780B6 (pt)
DE (1) DE69422726T2 (pt)
DK (1) DK0728144T3 (pt)
ES (1) ES2143611T3 (pt)
FI (1) FI961976A0 (pt)
GB (1) GB9323165D0 (pt)
GR (1) GR3033103T3 (pt)
HK (1) HK1015139A1 (pt)
HU (1) HU217344B1 (pt)
NO (1) NO961888D0 (pt)
PL (1) PL180403B1 (pt)
PT (1) PT728144E (pt)
WO (1) WO1995013289A1 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2170158A1 (en) * 1993-08-23 1995-03-02 Roy A. Black Inhibitors of tnf-alpha secretion
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
MX9702487A (es) * 1994-10-05 1998-04-30 Darwin Discovery Ltd Compuestos peptidilo y su uso terapeutico como inhibidores de las metaloproteasas.
WO1996035711A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
CA2217859A1 (en) * 1995-05-10 1996-11-14 David Alan Owen Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
DE69625506T2 (de) * 1995-10-05 2003-07-24 Darwin Discovery Ltd Schwefelsubstituierte peptide als inhibitoren für metalloproteinasen und der tnf-freisetzung
WO1997012861A1 (en) * 1995-10-05 1997-04-10 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
AU711907B2 (en) * 1995-11-22 1999-10-21 Darwin Discovery Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumor necrosis factor (TNF)
JP3628335B2 (ja) 1996-01-23 2005-03-09 塩野義製薬株式会社 スルホン化されたアミノ酸誘導体およびそれを含有するメタロプロティナーゼ阻害剤
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
BR9708480A (pt) * 1996-04-04 1999-04-13 Hoffmann La Roche Uso dos derivados das tetrahidro-beta-cabolinas como agentes antimetastáticos
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
CN1230884A (zh) * 1996-07-22 1999-10-06 孟山都公司 硫羟砜金属蛋白酶抑制剂
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
WO1998039024A1 (en) * 1997-03-03 1998-09-11 Darwin Discovery Limited Selective mmp inhibitors having reduced side-effects
JP2002515901A (ja) 1997-03-04 2002-05-28 モンサント カンパニー 芳香族スルホニルα−シクロアミノヒドロキサム酸化合物
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
CN1279669A (zh) 1997-11-14 2001-01-10 G·D·瑟尔公司 芳族砜异羟肟酸金属蛋白酶抑制剂
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
ES2203226T3 (es) * 1998-12-31 2004-04-01 Aventis Pharmaceuticals Inc. Amidomalonamidas y su uso como inhibidores de las metaloproteinasas de la matriz.
EA005500B1 (ru) 1999-02-08 2005-02-24 Дж.Д. Сирл Ллк Сульфаматогидроксамовая кислота как ингибитор металлопротеаз
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
CA2374555A1 (en) * 1999-06-15 2000-12-21 Merck & Co., Inc. Thiol derivative, metallo-beta-lactamase inhibitors
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
AU2001245862A1 (en) * 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
CN1425004A (zh) 2000-03-21 2003-06-18 宝洁公司 含杂环侧链的n－取代的金属蛋白酶抑制剂
BR0109354A (pt) * 2000-03-21 2003-04-15 Procter & Gamble Inibidores de metaloproteases os quais contêm cadeias laterais carbocìclicas
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
HUP0304069A2 (hu) 2001-05-11 2004-04-28 Pharmacia Corp. Aromás szulfon-hidroxamátok és proteázgátlókként való alkalmazásuk
MXPA04010555A (es) 2002-04-25 2005-02-17 Pharmacia Corp Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
DE202010018378U1 (de) 2009-04-10 2016-04-07 Tufts Medical Center, Inc. PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1)
JP2019525947A (ja) 2016-06-01 2019-09-12 エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK681287A (da) * 1986-12-24 1988-06-25 Beecham Group Plc Hidtil ukendte forbindelser
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
WO1994007481A1 (en) * 1992-10-02 1994-04-14 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
DE69422726T2 (de) 2000-06-08
AU679286B2 (en) 1997-06-26
JPH09505041A (ja) 1997-05-20
KR960705843A (ko) 1996-11-08
HU217344B1 (hu) 2002-02-28
CZ287780B6 (en) 2001-02-14
HU9601244D0 (en) 1996-07-29
ES2143611T3 (es) 2000-05-16
CA2173470A1 (en) 1995-05-18
PT728144E (pt) 2000-07-31
GB9323165D0 (en) 1994-01-05
FI961976A (fi) 1996-05-09
PL180403B1 (pl) 2001-01-31
US5853623A (en) 1998-12-29
EP0728144A1 (en) 1996-08-28
CN1134705A (zh) 1996-10-30
FI961976A0 (fi) 1996-05-09
NO961888L (no) 1996-05-09
AU8113394A (en) 1995-05-29
GR3033103T3 (en) 2000-08-31
ATE188969T1 (de) 2000-02-15
WO1995013289A1 (en) 1995-05-18
CZ134996A3 (en) 1996-10-16
DE69422726D1 (de) 2000-02-24
HUT73799A (en) 1996-09-30
EP0728144B1 (en) 2000-01-19
DK0728144T3 (da) 2000-07-03
HK1015139A1 (en) 1999-10-08
PL314300A1 (en) 1996-09-02
NO961888D0 (no) 1996-05-09

Similar Documents

Publication Publication Date Title
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
PT1119362E (pt) Metodos de utilizacao de compostos tetraciclina para aumentar a producao de interleucina-10
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
DE1019040T1 (de) Hemmung von p38 kinase aktivität durch arylharnstoff
ATE529109T1 (de) Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
EA199900494A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
ATE113208T1 (de) Verwendung des wirkstoffs azelastin zur bekämpfung von psoriasis-erkrankungen.
ID21698A (id) Karboksamida-karboksamida aril bisiklik dan penggunaan terapinya
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ES2189165T3 (es) Nuevos compuestos macrociclicos como inhibidores de metaloproteasa.
SE8901342D0 (sv) Biological materials, processes for producing biological materials and for using such materials in therapy
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
NO972906D0 (no) 4,4-(Disubstituerte)cykloheksan-1-ol-monomerer og beslektede forbindelser
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
GR920100519A (el) Ενώσεις.

Legal Events

Date Code Title Description
FA Application withdrawn